Araris Biotech AG, a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), has announced its first collaboration agreement. The Swiss start-up will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd.
Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for high efficacy and tolerability. With a strong commitment to transforming the landscape of ADCs, Araris leverages its proprietary, ready-to-use linker-payload platforms and site-specific conjugation techniques to create a new frontier in targeted therapeutics.
The company entered a collaboration with Taiho Pharmaceutical, a Japanese R&D-driven specialty pharma company with a focus on oncology. ADCs delivered by Araris will be further tested and evaluated by Taiho. The financial terms of the collaboration agreement were not disclosed.
“We are proud to enter a collaboration with Taiho Pharmaceutical and look forward to working with the Taiho team to develop next-generation ADCs with improved efficacy and tolerability,” said Dragan Grabulovski, Ph.D., acting chief executive officer of Araris.
Philipp Spycher, Ph.D., chief scientific officer of Araris added, “This agreement underlines the potential of our linker-payload platform to deliver novel ADCs with excellent properties, and it positions our company as a highly attractive partner for pharmaceutical companies.”
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines